公开(公告)号：AU2003224162B2

公开(公告)日：2008-06-12

申请号：AU2003224162

申请日：2003-04-02

Applicant: SOLVAY PHARM BV

Inventor： MCCREARY ANDREW C ,  BAKKER WOUTER I IWEMA ,  SCHARRENBURG GUSTAAF J M VAN ,  COOLEN HEIN K A C ,  KUIL GIJSBERT D ,  MAARSEVEEN JAN H VAN ,  HESSELINK MAYKE B ,  BOER DIRK DE

IPC: C07D471/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：NO20044775A

公开(公告)日：2004-12-16

申请号：NO20044775

申请日：2004-11-03

Applicant: SOLVAY PHARM BV

Inventor： SCHARRENBURG GUSTAAF JOHAN MAR ,  MCCREARY ANDREW C ,  MAARSEVEEN JAN H VAN ,  BAKKER WOUTER I IWEMA ,  COOLEN HEIN K A C ,  BOER DIRK DE ,  HESSELINK MAYKE B ,  KUIL GIJSBERT D

IPC: C07D471/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D487/04

公开(公告)号：DE60328272D1

公开(公告)日：2009-08-20

申请号：DE60328272

申请日：2003-04-02

Applicant: SOLVAY PHARM BV

Inventor： DE BOER DIRK ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  IWEMA BAKKER WOUTER I ,  KUIL GIJSBERT D ,  VAN MAARSEVEEN JAN H ,  MCCREARY ANDREW C ,  VAN SCHARRENBURG GUSTAAF J M

IPC: C07D471/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：BR0306148A

公开(公告)日：2004-10-19

申请号：BR0306148

申请日：2003-04-02

Applicant: SOLVAY PHARM BV

Inventor： BOER DIRK DE ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  BAKKER WOUTER I IWEMA ,  KUIL GIJSBERT D ,  MAARSEVEEN JAN H VAN ,  MCCREARY ANDREW C ,  SCHARRENBURG GUSTAAF J M

IPC: A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：AU2003224162A1

公开(公告)日：2003-10-20

申请号：AU2003224162

申请日：2003-04-02

Applicant: SOLVAY PHARM BV

Inventor： BOER DIRK DE ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  BAKKER WOUTER I IWEMA ,  KUIL GIJSBERT D ,  MAARSEVEEN JAN H VAN ,  MCCREARY ANDREW C ,  SCHARRENBURG GUSTAAF J M VAN

IPC: A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：ZA200404744B

公开(公告)日：2005-09-21

申请号：ZA200404744

申请日：2004-06-15

Applicant: SOLVAY PHARM BV

Inventor： BOER DIRK DE ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  IWEMA BAKKER WOUTER I ,  KUIL GIJSBERT D ,  MAARSEVEEN VAN JAN H ,  MCCREARY ANDREW C ,  SCHARRENBURG VAN GUSTAAF J M

IPC: A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00 ,  C07D ,  A61K ,  A61P

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：HK1070356A1

公开(公告)日：2005-06-17

申请号：HK05102968

申请日：2005-04-08

Applicant: SOLVAY PHARM BV

Inventor： BOER DIRK DE ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  IWEMA BAKER WOUTER I ,  KUIL GIJSBERT D ,  MAARSEVEEN VAN JAN H ,  MCCREARY ANDREW C ,  SCHARRENBURG VAN GUSTAAF J M

IPC: C07D20060101 ,  A61K20060101 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P20060101 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：NO20044775L

公开(公告)日：2004-12-16

申请号：NO20044775

申请日：2004-11-03

Applicant: SOLVAY PHARM BV

Inventor： SCHARRENBURG GUSTAAF JOHAN MAR ,  MCCREARY ANDREW C ,  MAARSEVEEN JAN H VAN ,  BAKKER WOUTER I IWEMA ,  COOLEN HEIN K A C ,  BOER DIRK DE ,  HESSELINK MAYKE B ,  KUIL GIJSBERT D

IPC: A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D471/04 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：PL371378A1

公开(公告)日：2005-06-13

申请号：PL37137803

申请日：2003-04-02

Applicant: SOLVAY PHARM BV

Inventor： DE BOER DIRK ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  IWEMA BAKKER WOUTER I ,  KUIL GIJSBERT D ,  VAN MAARSEVEEN JAN H ,  MCCREARY ANDREW C ,  VAN SCHARRENBURG GUSTAAF J M

IPC: A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK 1 receptor antagonistic activity represented by the general formula (1) wherein: R 1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1-3C), R 2 and R 3 independently represent halogen, H, OCH 3 , CH 3 and CF 3 , R 4 , R 5 and R 6 independently represent H, OH, O-alkyl(1-4C), CH 2 OH, NH 2 , dialkyl(1-3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.1]oct-8-yl; R 4 and R 5 together may represent a keto, a 1,3-dioxan-2-yl or a 1,3-dioxolan-2-yl group, X represents either O or S, n has the value of 1, 2 or 3, a is the asymmetrical carbon atom 8a, 9a or 10a when n equals 1, 2 or 3 respectively The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions containing at least one of these compounds as an active ingredient.

公开(公告)号：AR039192A1

公开(公告)日：2005-02-09

申请号：ARP030101105

申请日：2003-03-28

Applicant: SOLVAY PHARM BV

Inventor： VAN SCHARRENBURG GUUSTAAF J M ,  DE BOER DIRK ,  COOLEN HEIN K A C ,  HESSELINK MAYKE B ,  IWEMA BAKKER WOUTER I ,  VAN MAARSEVEEN JAN H ,  MCCREARY ANDREW C ,  KUIL GIJSBERT D

IPC: A61K31/4985 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61P1/00 ,  A61P1/08 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/02 ,  A61P13/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10 ,  C07D519/00

Abstract: Un grupo de singulares derivados de diazabicicloalcano que tienen interesante actividad antagonista del receptor NK1 de neuroquinina, representados por la fórmula general (1) en donde: R1 representa fenilo, 2-indolilo, 3-indolilo, 3-indazolilo o benzo[b]tiofen-3-ilo, cuyos grupos pueden estar sustituidos con halógeno o alquilo C1-3; R2 y R3 representan independientemente halógeno, H, OCH3, CH3 y CF3, R4, R5 y R6 independientemente representan H, OH, O-alquilo C1-4, CH2OH, NH2, dialquil (C1-3)N, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo o morfolin-4-ilo sustituido con uno o dos grupos metilo o metoximetilo, morfolin-4-ilamino, morfolin-4-ilmetilo, imidazol-1-ilo, tiomorfolin-4-ilo, 1,1-dioxotiomorfolin-4-ilo o 3-oxa-8-azabiciclo[3.2.1]oct-8-ilo; R4 y R5 juntos pueden representar un grupo ceto, un grupo 1,3-dioxan-2-ilo o un grupo 1,3-dioxolan-2-ilo, X representa O ó S; n tiene el valor de 1, 2 o 3; a es el átomo de C asimétrico 8a, 9a o 10a cuando n es igual a 1, 2 o 3 respectivamente. También se refiere a un método para la preparación de los compuestos, y a composiciones farmacéuticas que contienen al menos uno de estos compuestos como un ingrediente activo.